June 24, 2021
A federal magistrate judge has recommended against shifting nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals from a company that challenged Anacor's patent for a toenail fungus treatment, citing an absence of evidence that Anacor pursued unreasonable infringement claims or patent defenses.